Literature DB >> 25681263

The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland.

V A H Coles1, R Chapman2, T Lanitis2, S M Carroll3.   

Abstract

Genital warts, 90% of which are caused by human papillomavirus types 6 and 11, are a significant problem in the UK. The cost of managing genital warts was previously estimated at £52.4 million for 2010. The objective of this study was to estimate the cost of genital warts management up to 2012 in the UK and by jurisdiction. Population statistics and the number of reported genital warts cases in genito-urinary medicine clinics were obtained and extrapolated to 2012. Cases of genital warts treated in primary care were estimated from The Health Improvement Network database. The number of visits and therapy required were estimated by genito-urinary medicine experts. Costs were obtained from the appropriate national tariffs. The model estimated there were 220,875 genital warts cases in the UK in 2012, costing £58.44 million (£265/patient). It estimated 157,793 cases in England costing £41.74 million; 7468 cases in Scotland costing £1.90 million; 7095 cases in Wales costing £1.87 million; and 3621 cases in Northern Ireland costing £948,000. The full National Health Service costs for the management of genital warts have never previously been estimated separately for each jurisdiction. Findings reveal a significant economic burden, which is important to quantify when understanding the value of quadrivalent human papilloma virus vaccination.
© The Author(s) 2015.

Entities:  

Keywords:  Genital warts; HPV; cost; human papilloma virus; prevention; sexually transmitted infection; treatment; vaccination

Mesh:

Year:  2015        PMID: 25681263     DOI: 10.1177/0956462415573121

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  6 in total

1.  Incidence of external genital lesions related to human papillomavirus among Mexican men. A cohort study.

Authors:  Eduardo Lazcano-Ponce; Staci L Sudenga; B Nelson Torres; Mark Stoler; Leith León-Maldonado; Betania Allen-Leigh; Héctor Posso; Manuel Quiterio; María Del Pilar Hernández-Nevarez; Jorge Salmerón; Anna R Giuliano
Journal:  Salud Publica Mex       Date:  2018 Nov-Dec

2.  Estimating the Burden of Illness Related to Genital Warts in Russia: A Cross-Sectional Study.

Authors:  Vera N Prilepskaya; Mikhail Gomberg; Smita Kothari; Karen Yee; Amit Kulkarni; Suzanne M Garland; Anna R Giuliano
Journal:  J Health Econ Outcomes Res       Date:  2020-10-07

Review 3.  HPV Vaccination: An Underused Strategy for the Prevention of Cancer.

Authors:  Gilla K Shapiro
Journal:  Curr Oncol       Date:  2022-05-23       Impact factor: 3.109

4.  Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom.

Authors:  Kwame Owusu-Edusei; Cody Palmer; Olga Ovcinnikova; Giampiero Favato; Vincent Daniels
Journal:  J Health Econ Outcomes Res       Date:  2022-06-06

Review 5.  The Reservoir of Persistent Human Papillomavirus Infection; Strategies for Elimination Using Anti-Viral Therapies.

Authors:  Ke Zheng; Nagayasu Egawa; Aslam Shiraz; Mayako Katakuse; Maki Okamura; Heather M Griffin; John Doorbar
Journal:  Viruses       Date:  2022-01-22       Impact factor: 5.048

6.  Photodiagnosis of genital herpes and warts within a specialist online sexual health service: an observational (mixed methods) study of user experience and clinical outcomes.

Authors:  Jessica Engen; Adam Black; Gillian Holdsworth; Chris Howroyd; Mollie Courtenay; Paula Baraitser
Journal:  BMJ Open       Date:  2021-11-11       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.